secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2025-07-01T23:59:59+00:00
Accession:  0001193125-25-153427
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jade Biosciences appoints Brad Dahms as CFO, enters manufacturing agreement with Patheon for JADE101
--------------------------------------------------------------------------------

- Brad Dahms appointed CFO effective July 14, 2025; base salary $500K, target bonus 40%, option for 526,000 shares vesting over 4 years.
- Patheon MSA covers cGMP manufacturing for JADE101 and future programs; initial 5-year term with auto-renewal; non-cancellable fees per project.
- Dahms previously CFO of IDRx (sold to GSK), Theseus (sold to Concentra), and Selecta; brings 15 years biotech and investment banking experience.
- Company advancing JADE101 into clinic this year for IgA nephropathy; recent Nasdaq listing and private financing provide momentum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000119312525153427/0001193125-25-153427-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000119312525153427/d71010d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-153427

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer